Malik Fady Ibraham 4

What Happened Malik Fady Ibraham, Executive Vice President of Research & Development at Cytokinetics (CYTK), exercised 3,500 derivative option shares and sold those 3,500 shares in an open-market transaction on May 5, 2026. The exercise shows 3,500 shares acquired at a $7.80 strike ($27,300 total), and a same-day sale of 3,500 shares at $77.37 each for proceeds of $270,795. A related derivative entry shows 3,500 shares disposed at $0.00, reflecting conversion/cancellation of the option instrument.

Key Details

• Transaction date: 2026-05-05
• Exercise (code M): 3,500 shares @ $7.80 → $27,300 (acquired)
• Sale (code S): 3,500 shares @ $77.37 → $270,795 (disposed, open-market)
• Derivative disposition: 3,500 @ $0.00 → $0 (reflects conversion/cancellation of the derivative)
• Shares owned after transaction: not specified in the provided filing excerpt
• No 10b5-1 plan, tax-withholding, or late-filing flag was disclosed in the provided data

Context The sequence (exercise followed by an immediate sale of the same shares) functions like a cashless exercise — the options were converted to shares and those shares were sold the same day. Sales by executives after exercising options are common for covering exercise costs or diversification and do not by themselves indicate a view on the company’s long-term prospects.